‘Early Covid-19 Vaccine May Be Imperfect’

The Covid-19 vaccine from most companies is advancing into the last phase of human trials. There are many noted organizations like AstraZeneca, Pfizer, Sanofi, BioNTech, Novavax, Moderna, Merck, GlaxoSmithKline, Johnson & Johnson committed to developing the Covid-19 vaccine.

While the exact time period in which the vaccine could be approved and administered is unknown for now, the UK Vaccine Taskforce Chair Kate Bingham opined that the first generation Covid-19 vaccines might not work for everyone and there are high chances that the vaccine will be imperfect.

Bingham warned that the first-generation vaccines are likely to be imperfect and that we should be prepared they might not prevent the infection, except they might reduce symptoms. Bingham in his article published in The Lancet Medical Journal wrote the vaccine might not work for everyone or for long.

Bingham said the Vaccine Taskforce recognizes that possibly all of these vaccines could fail. She also raised doubts about the UK’s manufacturing capabilities for the billions of doses. A recent study in London found that antibodies in the British population during the summer have gone down and they being immune to infection many not last long.

The British government is keen on fighting back the virus, as the research assumes that the second wave of coronavirus will be strong and deadly than the first.